INVESTOR ALERT: Investigation of NanoViricides, Inc. Announced by Glancy Binkow & Goldberg LLP

LOS ANGELES--()--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or the “Company”) (NYSE MKT:NNVC) concerning possible violations of federal securities laws. NanoViricides is a nano-biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics for the treatment of viral infections. The investigation is focused on the Company’s business, operations and financial performance.

Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

The investigation is related to a report published February 11, 2014, on SeekingAlpha alleging that NanoViricides is a “House of Cards with -80% downside,” and “a vehicle designed specifically to enrich insiders.” The SeekingAlpha report claims that numerous examples of certain NanoViricides managers “abusing shareholders and looting the company” are outlined in a shareholder derivative complaint, Yidam, Ltd. v. Anil Diwan, et al., Case No. 1:13-cv-01777-RM-BNB, filed July 5, 2013, in the United States District Court for the District of Colorado.

If you purchased NanoViricides shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

Contact Glancy Binkow & Goldberg LLP if you purchased NanoViricides, Inc. securities before February 11, 2014.

Sharing

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340
shareholders@glancylaw.com
www.glancylaw.com